Real-world non-interventional long-term post-authorisation safety study of ruxolitinib in myelofibrosis.

Barraco, F; Greil, R; Herbrecht, R; Schmidt, B; Reiter, A; Willenbacher, W; Raymakers, R; Liersch, R; Wroclawska, M; Pack, R; Burock, K; Karumanchi, D; Gisslinger, H

View this publication in the PUBMED database